European Journal of Heart Failure

Article	Citations
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices	1556
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?	226
Striving for the ‘perfect’ definition of iron deficiency in heart failure	148
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’	137
	135
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail	130
Heart failure: age is no excuse for complacency	121
Dissecting the heart failure phenotype through phenomics	120
Issue Information	111
Risk factors for the development of heart failure in patients with or without prior myocardial infarction	109
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES	103
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival	103
Abstract	99
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials	99
Issue Information	93
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial	91
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	79
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction	77
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold	76
Letter regarding the article ‘Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair	72
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up	67
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock	66
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices	66
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’	63
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management	63

Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial	62
Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article ‘Medication adherence in patients with acutely decompensated heart failure	60
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h	60
Abstract	59
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF	59
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE	59
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials	59
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	57
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases	57
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial	56
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians	55
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure	55
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC	55
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery	55
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology	54
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial	54
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato	53
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters	53
Issue Information	53
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction	52
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities	52
Issue Information	52
	51
The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis	51
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models	51
Use of mechanical circulatory support in patients with non‐ischaemic cardiogenic shock	51
The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial	51
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis	50
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure	50
Remote patient management of heart failure across the ejection fraction spectrum: A pre‐specified analysis of the TIM‐HF2 trial	50
Predicting survival in patients with severe heart failure: Risk score validation in the HELP‐HF cohort	50
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation	49
Corrigendum to ‘Congestion in heart failure: A circulating biomarker‐based perspective’ and articles listed below	49
Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction	48
Serial direct sodium removal in patients with heart failure and diuretic resistance	48
Low blood pressure and the effect of empagliflozin in acute heart failure: An EMPULSE analysis	47
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions	47
Letter regarding the article ‘Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and	47
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’	46
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing	46
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?	46
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research	46
Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study	45
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation	45
Heart failure improvement, remission, and recovery: A European Journal of Heart Failure expert consensus document	45
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’	45
Revascularization in ischaemic heart failure with preserved ejection fraction: a nationwide cohort study	45
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy	44
Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction	43
Cardiac autonomic neuropathy and risk of incident heart failure among adults with type 2 diabetes	43

Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors	42
The cost‐effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health‐economic analysis of the DELIVER trial	42
Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced	42
Systemic embolism in transthyretin amyloid cardiomyopathy: how to look into the future	41
	41
	41
Reply to ‘Sodium–glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction – lessons from clinical trials’	41
Health status across major subgroups of patients with heart failure and preserved ejection fraction	41
	40
The impact of early surgery on mortality in infective endocarditis complicated by heart failure – How much more data do we need?	40
Reply to the letter regarding the article ‘Head‐to‐head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines’	39
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction	39
Artificial intelligence in heart failure improving the efficiency or dependency on it? Letter regarding the article ‘Artificial intelligence and heart failure: A state‐of‐the‐art review’	39
Video thermography uncovers relationship between volume status and temperature in heart failure	38
Issue Information	38
Remote pulmonary artery pressure‐guided management of patients with heart failure: A clinical consensus statement of the Heart Failure Association (HFA) of the ESC	38
Clinical trials: conventional or pragmatic?	38
Sodium–glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?	38
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study	38
Supplement Article	38
Late diagnosis in cancer sparks outrage—so why not heart failure?	38
More than just a clinical syndrome: Biomarkers and echocardiography should be rapidly advised for anyone with suspected heart failure!	37
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation	37
No longer from pillar to post: The first effective step in treating heart failure with preserved ejection fraction	37
Analysing the accuracy of pressure measurements during exercise with pulmonary artery pressure sensors – Insights from the ACTION‐MEMS study	37
Predicting heart failure: The promise of proteomics	37
Long‐term survival after acute heart failure hospitalization: from observation to collaborative interventions	37
Corrigendum to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction”	36
Comparative effectiveness of sacubitril/valsartan versus angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved	36
Biventricular cardiac power reserve in heart failure with preserved ejection fraction	36
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	35
The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry	35
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multic	35
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial	35
Disproportionate exercise‐induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: a non‐invasive echocardiographic study	34
Letter regarding the article ‘Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction’	34
Cost‐effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA‐HF and DELIVER data	34
Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry	34
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis	34
Effect of pulmonary artery pressure‐guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta‐analysis of real‐world evidence with the Car	34
Comparison of pulmonary congestion severity using artificial intelligence‐assisted scoring versus clinical experts: A secondary analysis of BLUSHED‐AHF	34
Revolutionizing cardiogenic shock treatment: Is the microaxial flow pump the ultimate game changer?	33
Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy	33
Delivering more evidence for the specificities of heart failure with improved ejection fraction: New answers, new questions	33
Differential sex‐related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudina	33
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?	33
Decreased left ventricular ejection fraction is associated with increased mortality in sepsis: A retrospective cohort study	33
Reply to ‘Is sodium chloride supplementation ready for clinical practice in acute heart failure?’	33
Enrolling patients in cardiogenic shock trials: are we missing someone? Insights from the Italian AltShock‐2 registry	33
Heart failure after left atrial appendage occlusion: Insights from the LAAOS III randomized trial	33
Reporting quality of heart failure randomized controlled trials 2000–2020: Temporal trends in adherence to CONSORT criteria	32
Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC)	32
Trends in heart failure mortality in Sweden between 1997 and 2022	32
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan	31
Cardiac reverse remodelling with vericiguat: Victory or no victory?	31
Recovery of cardiac function following COVID‐19	31
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry‐based analysis	31
Reply to the letter regarding the article ‘Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure’	31
Sympathetic vasoconstrictor activity before and after left ventricular assist device implantation in patients with end‐stage heart failure	31
Issue Information	31
Issue Information	31
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF	31
The heart during iron deficiency: a non‐rechargeable battery?	31
Assessing health status after discharge for decompensated heart failure: a patient‐centred priority	31
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Associatio	31
Issue Information	30
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis	30
Reply to the letter regarding the article ‘Lower extremity lymphatic flow is associated with diuretic response in acute heart failure’	30
	30
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of	30
Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial	30
Early changes in renal function during rapid up‐titration of guideline‐directed medical therapy following an admission for acute heart failure	30
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure	30
Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction	30
On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF	30
End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)	29
Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: Treat the heart, cherish the kidney	29
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency	29
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER	29
Myocardial perfusion in cardiac amyloidosis	29

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure	29
Correction to ‘What's new in heart failure? May–June 2024’, ‘What's new in heart failure? June–July 2024’, ‘What's new in heart failure? August–September 2024’, ‘The month in heart failure! September	29
Transcatheter edge‐to‐edge repair: fix the heart, heal the liver	29
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases	29
Measures of left atrial function predict incident heart failure in a low‐risk general population: the Copenhagen City Heart Study	28
Parvovirus B19 – more than a bystander in the prognosis of non‐ischaemic heart failure	28
Management of patients with heart failure at high risk of hyperkalaemia: The CARE‐HK in HF registry	28
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	28
Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO‐HF trial	28
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial	28
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial	28
Clonal haematopoiesis of indeterminate potential is associated with progression of aortic valve stenosis	28
Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge‐to‐edge repair: Insights from EuroTR	27
Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum	27
Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy	27
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta	27
Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program	27
Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial	27
The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal	27
Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction	27
Preventive catheter ablation for ventricular arrhythmias in patients with end‐stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE‐	26
Transthyretin amyloidosis: the picture is getting clearer	26
Prioritizing prevention of de novo and worsening chronic heart failure	26
Reply to ‘Epicardial adipose tissue: does it mediate the cardio‐protective effects of sodium–glucose co‐transporter 2 inhibitors in subjects with heart failure?’ Letter regarding the article ‘Impact o	26
When and how? Two simple questions to determine cancer status and inform therapeutic decisions and trial design in heart failure	26
Effect of allogeneic adipose tissue‐derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction – the SCIENCE trial	26
Reply to the letter regarding the article ‘Acute heart failure after non‐cardiac surgery: incidence, phenotypes, determinants and outcomes’	25
Improve heart function to improve heart failure outcomes: the disease‐modifying effects of spironolactone	25
Corrigendum to ‘Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction’ [Eur J Heart Fail 2021; 23: 983–991]	25
When is the time right? Dancing on the tightrope: referral for upgrade to cardiac resynchronization therapy	25
Implementing the evidence – the true summit of evidence‐based care and the false peak of guidelines	25
Corrigendum to ‘Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials’ [Eur J Heart Fail 2016;18:684–692]	25
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial	25
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?	24
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial	24
A second wind for digitalis glycosides in heart failure?	24
Time to treat the climate and nature crisis as one indivisible global health emergency	24
Changes in natriuretic peptide levels following patiromer‐enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study	24
Impact of misclassification bias on interpretation of finerenone efficacy in chronic obstructive pulmonary disease and heart failure with mildly reduced or preserved ejection fraction: A critical appr	24
Growth differentiation factor‐15: A promising biomarker for early detection of pre‐heart failure	24
Worsening heart failure comes into focus, chronic heart failure takes a backseat	24
Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind	24
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the	24
Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation	24
Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge‐to‐edge repair – Results from the TriValve	24
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis	24
Bug attack! The rising importance of Chagas disease	23
Splanchnic nerve block with botulinum toxin for therapy of chronic heart failure – mechanism of action (SPONGE‐HF)	23
Right heart failure as a cause of pulmonary congestion in pulmonary arterial hypertension	23
The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management	23
Sodium chloride supplementation in acute heart failure: A closer look at SOLVRED‐AHF. Letter regarding the article ‘Sodium chloride versus glucose solute as a volume replacement	23
Peri‐procedural management of transcatheter mitral valve replacement in patients with heart failure	23
Early and short‐term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD‐HF)	23
If a patient does not require treatment with loop diuretics, do they really have heart failure?	23
Time to reconsider the perception and management of hypertensive heart disease	23
Reply to the letter regarding the article ‘Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis’	23
Letter regarding the article ‘Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with th	22
Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: EAT your heart out…?!	22
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	22
Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals	22
Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta‐analysis	22
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61	22
Pulmonary vascular disease in heart failure with preserved ejection fraction: the evidence grows	22
Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left‐sided valvular heart disease in Europe. Insights from the ESC‐EORP Valvular	22
Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm A	22
Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes	21
Guideline‐directed medical therapy for heart failure in arrhythmia‐induced cardiomyopathy with improved left ventricular ejection fraction	21
Issue Information	21
Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction	21
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	21
A Heart Team approach to contemporary device decision‐making in heart failure	21
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease	21
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	21
Reply to: ‘What is the optimal dose of neurohormonal modulators in patients with heart failure? The higher the better?’	21
	21
New cardiovascular biomarkers in patients with advanced cancer – A prospective study comparing MR‐proADM, MR‐proANP, copeptin, high‐sensitivity troponin T a	20
Translating the 2021 ESC heart failure guideline recommendations in daily practice: Results from a heart failure survey. A scientific statement of the ESC Council for Cardiology	20
	20
	20
A clinical classification method with outstanding advantages for quickly identifying hazardous types	20
Examining the clinical role and educational preparation of heart failure nurses across Europe. A survey of the Heart Failure Association (HFA) of the European Society	20
A machine‐learning‐based prediction model in patients with takotsubo syndrome: ‘You can't stop change any more than you can stop the suns from setting!’	20
Giant cell myocarditis after first dose of BNT162b2 – a case report	20
Time for differential weight management in heart failure	20
Heart failure related central sympathetic activation: debunking the ‘holy grail’?	20
Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry	19
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS‐HF trial	19
Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides	19
Comorbidity trajectories before and after the diagnosis of heart failure: A UK Biobank cohort study	19
The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis	19
Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborativ	19
Effect of phosphodiesterase‐5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double‐blind, randomized, placebo‐controlled trial: SERVE	19
Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the VECTOR‐HF trial	19
In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial	19
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial	19